LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.

    Rezagholizadeh, Fereshteh / Tajik, Fatemeh / Talebi, Morteza / Taha, Seyed Reza / Shariat Zadeh, Mahdieh / Farhangnia, Pooya / Hosseini, Hamideh Sadat / Nazari, Aram / Mollazadeh Ghomi, Shabnam / Kamrani Mousavi, Seyede Mahtab / Haeri Moghaddam, Niloofar / Khorramdelazad, Hossein / Joghataei, Mohammad Taghi / Safari, Elahe

    Frontiers in immunology

    2024  Volume 15, Page(s) 1283364

    Abstract: Introduction: Pancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it ...

    Abstract Introduction: Pancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it is crucial to identify markers associated with immunological pathways in order to improve the treatment outcomes for this deadly cancer. The purpose of this study was to investigate the diagnostic and prognostic significance of three markers, CD8, CD68, and VISTA, in pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer.
    Methods: We analyzed gene expression data from Gene Expression Omnibus (GEO) database using bioinformatics tools. We also utilized the STRING online tool and Funrich software to study the protein-protein interactions and transcription factors associated with CD8, CD68, and VISTA. In addition, tissue microarray (TMA) and immunohistochemistry (IHC) staining were performed on 228 samples of PDAC tissue and 10 samples of normal pancreatic tissue to assess the expression levels of the markers. We then correlated these expression levels with the clinicopathological characteristics of the patients and evaluated their survival rates.
    Results: The analysis of the GEO data revealed slightly elevated levels of VISTA in PDAC samples compared to normal tissues. However, there was a significant increase in CD68 expression and a notable reduction in CD8A expression in pancreatic cancer. Further investigation identified potential protein-protein interactions and transcription factors associated with these markers. The IHC staining of PDAC tissue samples showed an increased expression of VISTA, CD68, and CD8A in pancreatic cancer tissues. Moreover, we found correlations between the expression levels of these markers and certain clinicopathological features of the patients. Additionally, the survival analysis revealed that high expression of CD8 was associated with better disease-specific survival and progression-free survival in PDAC patients.
    Conclusion: These findings highlight the potential of CD8, CD68, and VISTA as diagnostic and prognostic indicators in PDAC.
    MeSH term(s) Humans ; Carcinoma, Pancreatic Ductal/diagnosis ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/metabolism ; CD8-Positive T-Lymphocytes ; Pancreatic Neoplasms/diagnosis ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/metabolism ; Prognosis ; Transcription Factors ; CD8 Antigens/metabolism
    Chemical Substances Transcription Factors ; VSIR protein, human ; CD8 Antigens ; CD68 antigen, human
    Language English
    Publishing date 2024-01-30
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2024.1283364
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Smart Strategies for Precise Delivery of CRISPR/Cas9 in Genome Editing.

    Hasanzadeh, Akbar / Noori, Hamid / Jahandideh, Atefeh / Haeri Moghaddam, Niloofar / Kamrani Mousavi, Seyede Mahtab / Nourizadeh, Helena / Saeedi, Sara / Karimi, Mahdi / Hamblin, Michael R

    ACS applied bio materials

    2022  Volume 5, Issue 2, Page(s) 413–437

    Abstract: The emergence of CRISPR/Cas technology has enabled scientists to precisely edit genomic DNA sequences. This approach can be used to modulate gene expression for the treatment of genetic disorders and incurable diseases such as cancer. This potent genome- ... ...

    Abstract The emergence of CRISPR/Cas technology has enabled scientists to precisely edit genomic DNA sequences. This approach can be used to modulate gene expression for the treatment of genetic disorders and incurable diseases such as cancer. This potent genome-editing tool is based on a single guide RNA (sgRNA) strand that recognizes the targeted DNA, plus a Cas nuclease protein for binding and processing the target. CRISPR/Cas has great potential for editing many genes in different types of cells and organisms both
    MeSH term(s) CRISPR-Cas Systems/genetics ; DNA/genetics ; Gene Editing ; Genome ; RNA, Guide, CRISPR-Cas Systems/genetics
    Chemical Substances RNA, Guide, CRISPR-Cas Systems ; DNA (9007-49-2)
    Language English
    Publishing date 2022-01-18
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2576-6422
    ISSN (online) 2576-6422
    DOI 10.1021/acsabm.1c01112
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Histidine-enhanced gene delivery systems: The state of the art.

    Hooshmand, Seyyed Emad / Jahanpeimay Sabet, Makkieh / Hasanzadeh, Akbar / Kamrani Mousavi, Seyede Mahtab / Haeri Moghaddam, Niloofar / Hooshmand, Seyed Aghil / Rabiee, Navid / Liu, Yong / Hamblin, Michael R / Karimi, Mahdi

    The journal of gene medicine

    2022  Volume 24, Issue 5, Page(s) e3415

    Abstract: Gene therapy has emerged as a promising tool for treating different intractable diseases, particularly cancer or even viral diseases such as COVID-19 (coronavirus disease 2019). In this context, various non-viral gene carriers are being explored to ... ...

    Abstract Gene therapy has emerged as a promising tool for treating different intractable diseases, particularly cancer or even viral diseases such as COVID-19 (coronavirus disease 2019). In this context, various non-viral gene carriers are being explored to transfer DNA or RNA sequences into target cells. Here, we review the applications of the naturally occurring amino acid histidine in the delivery of nucleic acids into cells. The biocompatibility of histidine-enhanced gene delivery systems has encouraged their wider use in gene therapy. Histidine-based gene carriers can involve the modification of peptides, dendrimers, lipids or nanocomposites. Several linear polymers, such as polyethylenimine, poly-l-lysine (synthetic) or dextran and chitosan (natural), have been conjugated with histidine residues to form complexes with nucleic acids for intracellular delivery. The challenges, opportunities and future research trends of histidine-based gene deliveries are investigated.
    MeSH term(s) COVID-19/therapy ; Gene Transfer Techniques ; Histidine/genetics ; Humans ; Nucleic Acids ; Transfection
    Chemical Substances Nucleic Acids ; Histidine (4QD397987E)
    Language English
    Publishing date 2022-02-27
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1458024-x
    ISSN 1521-2254 ; 1099-498X
    ISSN (online) 1521-2254
    ISSN 1099-498X
    DOI 10.1002/jgm.3415
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top